Apoptosis Inducer

ALK-IN-33 (Compound 8q) is an orally active ALK inhibitor with an IC₅₀ of 1.61 nM. ALK-IN-33 exhibits significant selective killing effect on ALK-positive cancer cells. ALK-IN-33 induces cell cycle arrest and apoptosis, effectively weakening the migration, invasion and long-term survival ability of cancer cells. ALK-IN-33 can be used for research on non-small cell lung cancer

FLT3/HDAC-IN-3 is a dual inhibitor of FLT3 and HDAC. FLT3/HDAC-IN-3 potently inhibits FLT3 (IC₅₀ = 14 nM), HDAC1 (IC₅₀ = 27 nM), HDAC6 (IC₅₀ = 20 nM), and FLT3^D853Y (IC₅₀ = 55 nM), exhibits weak activity against HDAC8, and shows no activity against HDAC4. FLT3/HDAC-IN-3 possesses kinase selectivity, plasma stability, and stability in human liver microsomes. FLT3/HDAC-IN-3 demonstrates anti-proliferative effects in a variety of hematological malignancy cell lines. FLT3/HDAC-IN-3 shows efficacy in the Jeko-1 xenograft model without observed significant toxicity. FLT3/HDAC-IN-3 can be used in the study of hematological malignancies.

7-epi-Isogarcinol is a polycyclic polyprenylated acylphloroglucinol (PPAP), with moderate antiproliferative activity. 7-epi-Isogarcinol blocks STAT3 signaling pathway, to induce apoptosis and inhibit cell migration.

Anticancer agent 64 (compound 5m) shows cytotoxic activity in CCRF-CEM cells, with IC₅₀ of 2.4 μM. Anticancer agent 64 shows good anticancer activity through apoptosis induction. Anticancer agent 64 induces caspase 3 and 7 activation and PARP cleavage. Anticancer agent 64 induces significant effect of mitochondria depolarization.

4,4′-Secalonic acid D (Compound 12) is a PARP1 inhibitor. 4,4′-Secalonic acid D induces the accumulation of ROS and DNA damage, activates the caspase-3/GSDME pathway, and triggers apoptosis and pyroptosis of tumor cells by inhibiting PARP1. 4,4′-Secalonic acid D has anti-tumor activity.

6'-BPANeuGc is a CD22-targeting ligand. 6'-BPANeuGc suppresses BCR activation, recruits CD22 to B cell immunological synapses, initiates inhibitory signals, induces B cell apoptosis. 6'-BPANeuGc inhibits calcium flux, and inhibits Akt and Erk activation. 6'-BPANeuGc can be used for research on immune system diseases.

Antitumor photosensitizer-5 (Ru2) is a photosensitizer which effectively target tumor mitochondria with an IC₅₀ of 0.3 μM for phototoxicity to A549 cells. Under 460 nm light irradiation, antitumor photosensitizer-5 induces the generation of reactive oxygen species and NADH depletion, causes mitochondrial damage and activation of caspase-3, inducing apoptosis and suppressing cell migration. Antitumor photosensitizer-5 has the potential to prevent the growth of malignant tumors, therefore, shows the potential to be applied to photodynamic therapy.

Cimicifugic acid A is a cytotoxic caffeic acid derivative that can be isolated from the rhizomes of Cimicifuga heracleifolia. Cimicifugic acid A shows cytotoxic activity against cancer cells, and increases expression of cleaved PARP, thereby exhibiting pro-apoptotic activity. Cimicifugic acid A can be used for colon cancer research.

PROTAC BET Degrader-15 is a BET PROTAC degrader with DC₅₀ values of <0.10 nM, <0.01 nM, and <0.01 nM against BRD2, BRD3, and BRD4, respectively. PROTAC BET Degrader-15 induces significant G2/M phase cell cycle arrest and triggers apoptosis. PROTAC BET Degrader-15 causes marked downregulation of c-Myc, accompanied by upregulation of the cell cycle inhibitory protein p21, downregulation of CDK6, and an increase in the apoptosis marker cleaved PARP. PROTAC BET Degrader-15 is applicable to the research of hematologic malignancies and lung cancer.

EGFR/VEGFR2-IN-9 (Compound 9b) is an inhibitor of VEGFR-2 (IC₅₀ = 1.325 μM) and EGFR (IC₅₀ = 1.891 μM). EGFR/VEGFR2-IN-9 significantly inhibits the proliferation of multiple cancer cell lines, particularly leukemia cells. EGFR/VEGFR2-IN-9 upregulates the expression levels of Bax, caspase-3, and p53, while downregulating the expression of Bcl-2. EGFR/VEGFR2-IN-9 induces apoptosis and arrests the cell cycle in the G1 phase. EGFR/VEGFR2-IN-9 can be used to investigate anti-tumor angiogenesis and multi-drug resistant cancers.

rac-Lenalidomide-¹³C₅ (CC-5013-¹³C₅) is the ¹³C₅-labeled Lenalidomide (HY-A0003). Lenalidomide (CC-5013) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide promotes IL-2 release and effector functions of CD8⁺ T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide can be used in research related to hematological malignancies, acute liver failure and acute kidney injury.

Apoptosis inducer 39 is an apoptosis inducer with IC₅₀s of 4.53 and 15.42 μM against MDA-MB-231 and A549 cells. Apoptosis inducer 39 exerts in vitro anti-tumor activity by decreasing the expression of the anti-apoptotic protein Bcl-2 while increasing the expression of the pro-apoptotic protein Bax. Apoptosis inducer 39 can be used for the study of breast cancer and non-small lung cancer.

Bcl-2-IN-20 (Compound 81) is an inhibitor for Bcl-2 with IC₅₀ <10 μM (79.1% inhibition at 9 μM). Bcl-2-IN-20 exhibits cytotoxicity in SK-MEL-28 (IC₅₀>10 μM), A549 (IC₅₀=6.1 μM), HepG2 (IC₅₀>10 μM), MCF-7 (IC₅₀=8.9 μM), HCT116 (IC₅₀>10 μM) and HEK-293 (IC₅₀=14.1 μM). Bcl-2-IN-20 promotes the ROS production, induces apoptosis and DNA damage.

BTK-IN-7 is a potent and selective inhibitor of BTK (IC₅₀=4.0 nM). BTK-IN-7 has high selectivity in both enzymatic (ITK >250-fold, EGFR >2500-fold) and cellular levels (ITK >227-fold, EGFR 27-fold). BTK-IN-7 also has potent antitumor activity.

Thalidomide-piperidine-C-2,6-diazaspiro[3.3]heptane-C2-OH is a conjugate of E3 ligase ligand and linker, consisting of Thalidomide (HY-14658) and the corresponding Linker. Thalidomide-piperidine-C-2,6-diazaspiro[3.3]heptane-C2-OH can serve as a Cereblon ligand to recruit CRBN protein and serve as a key intermediate for the synthesis of complete PROTAC molecules.

Ancitabine (hydrochloride) (Standard) is the analytical standard of Ancitabine (hydrochloride). This product is intended for research and analytical applications. 0

Apoptosis inducer 59, a camphorsulfonamide-based thiazolylhydrazone derivative, is a apoptosis inducer with antitumor activity. Apoptosis inducer 59 can inhibit cell migration and invasiveness, cause S phase arrest, induce ROS production and depolarise mitochondrial membrane potential. Apoptosis inducer 59 can be used for the research of cancer, such as breast cancer.

4-Epianhydrotetracycline hydrochloride is a major intermediate product of Tetracycline (HY-A0107). 4-Epianhydrotetracycline hydrochloride shows lethal effects and induces cell apoptosis of zebrafish embryos. 4-Epianhydrotetracycline hydrochloride inhibits Shewanella, E. coli and P. aeruginosa with MIC values of 2, 1 and 64 mg/L, respectively.

C16-Ceramide (d18:1/16:0) (Standard) is the analytical standard of C16-Ceramide (d18:1/16:0) (HY-100354). This product is intended for research and analytical applications. C16-Ceramide (d18:1/16:0) is a natural small molecule activating p53 through the direct and selective binding.

Anticancer agent 358 is a PARP inhibitor with antiproliferative activity against lung cancer cells and low toxicity to normal hepatocytes. Anticancer agent 358 binds to the active site of PARP via hydrogen bonds and π-π interactions with key residues, thereby promoting the accumulation of DNA damage. Anticancer agent 358 induces DNA damage, apoptosis, and autophagy in lung cancer cells. Anticancer agent 358 can be used for the research of non-small cell lung cancer.